At the 2025 ESMO Congress, meaningful discussions among physicians, patients, and the industry underscored a clear theme, that the field of oncology is rapidly advancing toward new horizons.
From these sessions, CRA’s Aaron Everitt highlighted that while there are still relevant data releases and findings on existing immune checkpoint inhibitors, antibody-drug conjugates (ADCs) are now commanding much of the spotlight. Moreover, there is mounting excitement and anticipation regarding the emerging roles of bispecific antibodies (bsAbs) and novel radioligands in treating a broad range of cancers.
